Università degli Studi di Ferrara
Quick facts
Marketed products
- abciximab bolus only regimen · Cardiovascular
Abciximab is a chimeric monoclonal antibody that blocks the glycoprotein IIb/IIIa receptor on platelet surfaces, preventing platelet aggregation and thrombus formation. - Blood component A
- Blood component B
- bolus+infusion
A bolus-infusion regimen delivers a rapid initial dose followed by continuous or repeated slower administration to achieve and maintain therapeutic drug levels. - Bronchodilator Agents · Respiratory
Bronchodilator agents relax airway smooth muscle to increase airway diameter and improve airflow to the lungs. - Mepolizumab 100 MG
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: